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Mutation of Solute Carrier SLC16A12 Associates
with a Syndrome Combining Juvenile Cataract
with Microcornea and Renal Glucosuria
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John Neidhardt,1 Christina Zeitz,1,9 Peter Nu¨rnberg,4,5 Isaak Schipper,3 and Wolfgang Berger1
Unobstructed vision requires a particular refractive index of the lens, a measure based on the organization of the structural proteins
within the differentiated lens cells. To ensure an intact lens structure, homeostasis within the lens cells is indispensable. Alterations
of the lens structure result in opacity and lead to cataract. Renal glucosuria is deﬁned by elevated glucose level in the urine without
hyperglycemia and without evidence of morphological renal anomalies. In a Swiss family with autosomal dominant juvenile cataract,
microcornea, and renal glucosuria, we have identiﬁed a nonsensemutation in amember of the carboxylic acid transporter family SLC16.
The underlying gene defect in SLC16A12 resides within a 3 cM region on chromosome 10q23.13 deﬁned by linkage mapping of this
phenotype. We found tissue-speciﬁc variability of SLC16A12 transcript levels in control samples, with high expression in the eye and
kidney, the two organs affected by this syndrome. This report demonstrates biological relevance of this solute carrier. We hypothesize
that SLC16A12 is important for lens and kidney homeostasis and discuss its potential role in age-related cataract.Lens transparency, a requirement of unobstructed vision,
is achieved by ordered events of cell differentiation accom-
panied by controlled arrangement of proteins, mainly crys-
tallins. Differentiation of the lens cells follows a precise
sequence of events.1 Mitotic activity of a small number
of lens epithelial cells (LEC) provides a continuous supply
of new cells that, upon signal-induced differentiation, will
begin with a cellular elongation process, followed by the
breakdown of the nucleus and organelles. Concomitantly,
some but not all metabolic activity ceases. Tightly packed,
highly elongated cells comprise the several millimeter-
thick lens structure. Changes in this structure, composi-
tion, or the assembly of the structural proteins, of which
crystallines make about 90%, will result in alteration of
the refractive index. This increasing opacity of the lens is
termed cataract. Deﬁned by age of onset, one distinguishes
between congenital (infantile), juvenile, and age-related
cataract. The ﬁrst two, also referred to as childhood cata-
ract, show wide heterogeneity with respect to the genetic
and phenotypic aspects.2 Frequently, mutations that dis-
turb the development of the lens occur in structural lens
proteins and will lead to childhood cataract. Among the
genetic factors that inﬂuence age-related cataract, no genes
with mutations have yet been identiﬁed. Genes involved
in recessively or dominantly inherited cataract encode
structural components of the lens cells but also compo-
nents of the cytoskeleton, of the cell membrane, transcrip-
tion factors, metabolic proteins, chromatin-modifyingprotein 4B, and the gene TMEM114, encoding a protein
with four predicted transmembrane domains but of un-
known function.3–6
Occasionally, cataract is accompanied by additional
symptoms, among them microcornea.4,5 Of particular
interest to this work is a Swiss family with juvenile cataract,
associated with microcornea and renal glucosuria.7 Al-
though renal glucosuria is not considered a disease,
affected individuals show characteristic elevation of glu-
cose concentration in the urine, without evidence of other
renal tubular defects. The pattern of inheritance has been
described as codominant with variable penetrance.8 In
the family described by Vandekerckhove and colleagues,7
9 of 12 cataract patients also showed elevated levels of glu-
cose in their urine, in the absence of any other renal or
metabolic abnormalities (Figures 1 and 2; Table 1).
Determination of the underlying genetic defect and
whether cataract and glucosuria are caused by the same
pathogenic alteration was subject of this study. We began
with linkage analysis with the Affymetrix GeneChip Hu-
man Mapping 10K Array, version 2.0 (Affymetrix, Santa
Clara, CA). Nonparametric linkage analysis with all geno-
types of a chromosome simultaneously was carried out
with MERLIN, and parametric linkage analysis was per-
formed by the program ALLEGRO9 assuming a disease
allele frequency of 0.0001 and autosomal dominant inher-
itance with full penetrance for cataract. Haplotypes were
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Figure 1. Pedigree of Swiss Family
Segregating Juvenile Cataract with
Microcornea and Glucosuria
Modified after Vandekerckhove et al.7
Filled symbols represent affected status
for all three phenotypes, with three excep-
tions indicated by star; III-1 and III-2 are
negative and III-5 is borderline for gluco-
suria (Table 1). Five-digit laboratory iden-
tification numbers (given below pedigree
symbols) were assigned prior to DNA ex-
traction. Family members IV-2 and IV-3
were not tested for any of the three pheno-
types.with HaploPainter.10 Results predicted that the disease-
causingmutation for the juvenile cataract andmicrocornea
maps to an interval on chromosome 10q23.31 (Figure 3) of
3 cM, spanning between the SNP markers rs701826 and
rs2254391 (Figure 4). For the glucosuria phenotype, no sig-
niﬁcant LOD score was obtained (data not shown), proba-
bly resulting from incomplete penetrance. Calculations of
50% penetrance for affected patients revealed a LOD score
slightly above 2 on a region of chromosome 10, which
overlaps with the 3 cM interval for cataract. These ﬁndings
suggest that more affected family members are required to
obtain a signiﬁcant LOD score for glucosuria.
The NCBI map viewer (Build 36.2, August 2007) dis-
played 31 genes and 3 phenotypes (selection shown in
Figure 2. Cataract and Microcornea Phenotype of Patient III-5
Preoperative cortico-nuclear cataract in right eye is shown in (A)
and microcornea (9.8 3 9.5 mm) in (B).TheTable 2) within the linkage interval on chromosome
10q23.31. Among the phenotypes, none seemed obviously
related to cataract. Distal to this linkage interval maps the
homeobox gene PITX3 (MIM 602669). Mutations in this
gene are known to cause the dominant form of congenital
cataract and anterior segment mesenchymal dysgenesis
(ASMD).11,12 We performed sequence analysis in the DNA
of one affected patient (II-1) without ﬁnding a mutation
(data not shown; primer sequences are available upon
request).
Considering the function of each of the 31 genes within
the linkage interval, we reasoned that FAS and SLC16A12
were potential candidate genes. FAS (MIM 134637), en-
coding the tumor necrosis factor receptor super family
Table 1. Summary of Clinical Data
Pedigree ID Cataract Microcornea Glucosuria
II-1 þ þ þ
II-3 þ þ þ
II-5 þ þ þ
II-7 þ þ þa
II-9 þ þ þ
II-11 - - -
III-1 þ þ -a
III-2 þ þ -
III-4 þ þ þ
III-5 þ þ þ/b
III-7 þ þ þ
III-8 þ þ þ
III-9 - - þc
III-11 - - -
Pedigree identification numbers are taken from Figure 1. Presence/absence
of cataract, microcornea, and renal glucosuria is given asþ/. Assignment
of microcornea was given if values were below 11.0 mm. Glucosuria was
evaluated as positive (þ) if glucose concentration was above 0.8 mmol/L.
a Glucose values were generally obtained from postprandial samples except
for patients II-7 and III-1.
b Test performed during pregnancy.
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Figure 3. LOD Scores across the Genome for the Phenotype of Cataract with Microcornea
Chromosome number and genetic distances in cM (centi Morgan) is horizontally displayed; LOD score is given along the vertical axis.member 6, could play a role during differentiation of lens
cells.13 DNA sequence analysis did not reveal a coding
region mutation, but upstream of the transcription unit
we detected a deletion of six thymidin residues. This alter-
ation was also found in unaffected family members, so it
was excluded as disease causing. In addition, a deletion
of seven thymidin residues at the same site has been re-
ported as SNP rs3074157.
Metabolic requirements of the lens cells can be accom-
modated by establishing a transport system for small mole-
cules. The gene encoding the solute carrier SLC16A12
(ENSG00000152779, NCBI GeneID 387700) belongs to
a family of 14 monocarboxylate transporters.14 All mem-
bers display an average size of 40–50 kDa and are character-
ized by 12 transmembrane domains (TMDs). Besides DNA
sequence and gene annotation for SLC16A12, no informa-
tion on its genetic and biochemical properties was avail-
able.We sequenced the ﬁve coding exons (3 to 8) including
approximately 50–100 base pairs of their respective ﬂank-
ing introns andUTR regions (primer information inTable 3)
and found a heterozygous mutation in exon 6: c.643C/T,
which is predicted to lead to a premature termination co-
don p.Q215X (Figure 5). This mutation was found in all
12 cataract patients of the Swiss family whereas the three
unaffected individuals (II-11, III-9, and III-11) did not carry
this alteration. It was also absent in 370 normal alleles, two
ofwhichwere fromanunrelated spouse of the family (II-10)
(Figure 1). Thus, we considered SLC16A12 as the gene asso-
ciated with the development of this cataract.
Knowledge of the expression pattern of SLC16A12
would aid in understanding its effect on cataract with mi-
crocornea and glucosuria. For that purpose, we performed774 The American Journal of Human Genetics 82, 772–779, MarchRT-PCR experiments based on established procedures15
with RNA from several organs, including the two affected
structures, lens and kidney (Figure 6). In general, the solute
carrier was detected in retina, brain, lung, kidney, liver, and
testis, although at remarkably different levels. We com-
pared the amount of SLC16A12 transcripts with that of
the endogenous control transcripts from RNA polymerase
II gene, and we estimated that the solute carrier seemed
most highly expressed in kidney, followed by retina,
lung, and testis and very weakly in brain and liver (Fig-
ure 6B). The expected RT-PCR fragment was not detected
in blood cells (data not shown). In addition, we assayed
SLC16A12 transcripts isolated from human retina, retinal
pigment epithelial cells (RPE), and lens of a 47-year-old
eye donor lacking any signs of cataract and conﬁrmed
the expression pattern we had seen from purchased RNA
(Figures 6B and 6C). Importantly, SLC16A12 transcripts
were also detected in the human lens (Figure 6C). Because
only a very small portion of the lens, namely the lens epi-
thelial cells (LECs), may be transcriptionally active, we
concluded that expression of SLC16A12 in the LECs must
be relatively high. Our RT-PCR data show that SLC16A12
expression is regulated in a cell/tissue-speciﬁc manner.
These observations concur with the reported expression
patternofother SLC16 familymembers,whichcanbeeither
ubiquitous or tissue speciﬁc.14,16 Tissue-speciﬁc regulation
of SLC16A12 expression is further supported by the lack of
additional manifesting symptoms in the Swiss family.
This report provides the ﬁrst evidence (to our knowl-
edge) for the physiological function of SLC16A12. In com-
bination with the knowledge of the transport function
of other SLC16 isoforms, a prediction of molecular activity2008
Figure 4. Haplotypes for the Cataract-Linked Region on Chromosome 10
Recombinations in patients 26808 (III-4) and 26274 (IV-1) define a critical interval of 2.6 Mega bases (Mb) delimited by markers
SNP_A_1510595 (rs701826) (*) and SNP_A_1511227 (rs2254391) (**) at positions 108.48 and 111.55 cM, respectively. Disease chro-
mosome in red.is possible. These transporters are highly conserved
throughout evolution and can be found in prokaryotes as
well as eukaryotes, from yeast tomammals. They can trans-
port lactate, aromatic amino acids, short-chain fatty acids,
butyrate, ketones, or thyroid hormone in a proton-depen-
dent or -independent fashion.14 Subcellular localization of
some family members in the eye and also kidney points to
highly speciﬁc tasks of molecular transport.17,18 Although
neither the localization in the lens or kidney nor substrate
speciﬁcity of this transporter is known, we speculate that
its reduction would interfere with homeostasis. In the
lens, solutes need to move from the cortical lens epithelial
cells to the inner ﬁber cells. In the kidney, solutes also need
to move between tubular cells and blood.ThePrediction of membrane topology19 revealed a 536
amino acid protein containing 12 transmembrane do-
mains (TMDs) with both termini located intracellularly.
Whereas the large intracellular loop and both termini
show high variability in their amino acid sequence among
the different SLC16 family members, highest conservation
is found in the ﬁrst and ﬁfth TMD.14 The p.Q215X muta-
tion in SLC16A12 is located within the large cytoplasmic
loop near the fourth TMD (Figure 7), predicted to result
in a truncated protein with severely impaired or com-
pletely absent transport function. The premature termina-
tion codon might cause mRNA decay of the mutant allele,
possibly by the mechanism of nonsense-mediated decay,20
but a dominant-negative effect or gain of function of theAmerican Journal of Human Genetics 82, 772–779, March 2008 775
truncated protein can not be excluded. Consequently, re-
duced amounts of the normal allele in the patients could
account for a gradual, progressive nature of the cataract.
The resulting deﬁciency in transportation of metabolites
in the lens could lead to alteration of structural compo-
nents of the ﬁber cells and the refractive index, contribut-
ing to the development of cataract. Similarly, defective
transport in the kidney could lead to excessive accumula-
tion of glucose in the urine, making SLC16A12, directly or
indirectly, involved in glucose transport. Because the causes
of glucosuria can be heterogeneous, other factors, singly or
in combination with deﬁcient SLC transporter activity,
could result in the highly variable phene of glucosuria.
Although several arguments have been presented that
support a model in which cataract and glucosuria are
caused by the same mutation, we can not rule out that
Table 2. Phenotype and Loci that Map to the Linkage Interval
on Chromosome 10
Symbol Description MIM Position
Phenotypes
TNFRSF6 tumor necrosis factor
receptor superfamily,
member 6
134637 10q24.1
LIPA Wolman disease,
liposomal acid lipase
deficiency
278000 10q24-q25
SCZD11 schizophrenia
susceptibility locus
608078 10q22.3
Loci MIM or Ensembl GeneID
LIPF lipase, gastric 601980 8513
LIPK lipase, family
member K
ENSG00000204021 643414
LIPN member N ENSG00000204020 643418
LIPM member M ENSG00000173239 340654
ANKRD22 ankyrin repeat
domain 22
ENSG00000152766 118932
STAMBPL1 STAM binding
protein-like 1
ENSG00000138134 57559
ACTA2 actin, alpha 2,
smooth muscle,
ENSG00000107796 59
FAS Fas (TNF receptor
superfamily,
member 6)
134637 355
CH25H cholesterol
25-hydroxylase
604551 9023
LIPA lipase A, (Wolman
disease)
278000 3988
IFIT2 interferon-induced
protein with
tetratricopeptide
repeats 2
147040 3433
IFIT3 repeats 3 604650 3437
IFIT1L repeats 1-like ENSG00000204010 439996
IFIT1 repeats 1 147690 3434
IFIT5 repeats 5 ENSG00000152778 24138
SLC16A12 solute carrier family
16, member 12
(monocarboxylic acid
transporter 12)
ENSG00000152779 387700
MIRN107 microRNA 107 406901
PANK1 pantothenate kinase 1 606160 53354
MPHOSPH1 M-phase
phosphoprotein 1
605498 9585
HTR7 5-hydroxytryptamine
(serotonin) receptor 7
(adenylate cyclase-
coupled)
182137 3363
RPP30 ribonuclease P/MRP
30kDa subunit
606115 10556
ANKRD1 ankyrin repeat domain
1 (cardiac muscle)
609599 27063
NUDT9P1 nudix (nucleoside
diphosphate linked
moiety X)-type motif 9
pseudogene 1
119369
PCGF5 polycomb group ring
finger 5
ENSG00000180628 84333
HECTD2 HECT domain
containing 2
ENSG00000165338 143279
Table 2. Continued
Symbol Description MIM Position
Phenotypes
PPP1R3C protein phosphatase
1, regulatory
(inhibitor) subunit 3C
602999 5507
TNKS2 tankyrase, TRF1-
interacting ankyrin-
related ADP-ribose
polymerase 2
607128 80351
From the NCBI map viewer (Build 36.2, August 2007), we selected 27 anno-
tated genes, and all phenotypes located to the affected region on chromo-
some 10q23.31 are shown. For identification, MIM code, Ensembl code,
and/or GeneID (NCBI) is given.
Table 3. Primer Information
Gene - Exon - Direction Sequence Purpose
SLC16A12 ex3f gtctgccccagtctagtattca genomic sequencing
SLC16A12 ex3r cggaaatacacacacaccaca genomic sequencing
SLC16A12 ex4f ccctgtggtggttgaacact genomic sequencing
SLC16A12 ex4r tggctttggctgaagatagg genomic sequencing
SLC16A12 ex5f tctattccaaccctgctgct genomic sequencing
SLC16A12 ex5r ccagctctgtttaactgctagg genomic sequencing
SLC16A12 ex6af gaatgactggtgaggggaga genomic sequencing
SLC16A12 ex6ar aacagaacggagacggctaa genomic sequencing
SLC16A12 ex6bf cggggagccttactcattct genomic sequencing
SLC16A12 ex6br agtaccagcaagggagatgc genomic sequencing
SLC16A12 ex7f cacaatgggaaagccatctc genomic sequencing
SLC16A12 ex7r atggttttgggggctcttat genomic sequencing
SLC16A12 ex8f caaagttacaattggtggtgct genomic sequencing
SLC16A12 ex8r agttatgagcacaaatcccaaa genomic sequencing
SLC16A12exon3f caggaagtcactggacagca RT-PCR
SLC16A12exon5r caggaagtcactggacagca RT-PCR
SLC16A12exon4_5f gtgtgaccatgctctgtgct RT-PCR
SLC16A12exon6r aagacaaagcccccaagaat RT-PCR
RPII_cDNA_N20_F tgtggagatcttcacggtgct RT-PCR
RPII_cDNA_N234_R cataagcacgtccaccgtttc RT-PCR
The name of primers contains information about the gene (SLC16A12 or
POLR2A, exon, and direction, forward [f,F] or reverse [r,R]). The sequence
of primers points 50 to 30.
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the two diseases may segregate independently. In case of
an unlinked locus for glucosuria, examples of potential
candidates include the chaperone protein CD147, which
facilitates subcellular sorting of SLC16 members17 or
proteins involved in glucose transportation, i.e., GLUT
proteins21 or SLC5A2.8
Age-related cataract, which is the most common cause
for avoidable blindness worldwide, is known to be depen-
dent on both environmental risk factors and genetic fac-
tors. A twin study on the cortical type of age-related cata-
ract implies the action of dominant genes to account for
genetic heritability of about 50%.22,23 The progressive
course of juvenile cataract described here, resulting most
likely from defective transport of small molecules, suggests
the potential role of the SLC16A12 transporter in age-re-
lated cataracts as well. Depending on the type and location
of mutations within the SLC16A12 transporter, more or
less severe forms of cataract would be expected, which
may also vary in the time of onset. We propose that muta-
tions in a solute carrier such as SLC16A12 could lead to the
age-related form of cataract. Knowledge of the substrate
may open new venues for nonsurgical treatment.
Taken together, we show for the ﬁrst time (to our knowl-
edge) the biological relevance of the solute carrier
SLC16A12 and suggest a function in the establishment
and/or maintenance of homeostasis in the lens and prob-
ably also in the kidney.
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Figure 5. Mutation Screening in
SCL16A12
Electropherogram shows the mutation in
exon 6 within the context of 21 nucleo-
tides. Shown are both the DNA sequence
of the unaffected individual III-9 (A) and
the heterozygous change of C/T (Y) in
the affected individual III- 8 (B). The ge-
notypes are given in brackets. Translation
codons are underlined and amino acid
identity is written below with single letter
code.
Figure 6. Expression Studies of
SLC16A12
(A) Schematic representation of exons.
Protein coding regions are displayed in
darker shade. Translation initiates within
exon 3 (vertical arrow, ATG) and termi-
nates within exon 8 (vertical arrow,
STOP). Mutation, c.643C/T, in exon 6
(vertical arrow) is predicted to lead to
a premature termination. Positions of
primers are indicated by forward and re-
verse horizontal arrows, yielding RT-PCR
product a (exon spanning 4_5 to exon 6)
and product b (exon 3 to exon 5).
(B) RT-PCR analyses from human tissues
with commercially available mRNA. Primers
to yield product a were used to amplify SLC16A12 transcripts. RNA Polymerase II (POLR2A) transcripts served as endogenous control.
(C) RT-PCR analysis from tissues isolated from a single human donor eye. Primers to yield product b of SLC16A12 and of POLR2A (control)
were used for amplification. Lens RNA was 3-fold concentrated compared to the other samples.
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